99 | FIXED DURATION SUBCUTANEOUS MOSUNETUZUMAB IN PATIENTS WITH PREVIOUSLY UNTREATED HIGH‐TUMOR BURDEN FOLLICULAR LYMPHOMA: INTERIM RESULTS FROM THE PHASE II MORNINGSUN STUDY
Hematological Oncology | June 17, 2025 | Volume: 43 | Issue: S3 | Pages: No page available
10.1002/hon.70093_99